Navigation Links
NIH funds research to identify Parkinson's biomarkers
Date:2/14/2013

es.

According to Bowman, there are no diagnostic tests that confirm Parkinson's disease. Instead, physicians base Parkinson's diagnoses on a combination of medical history, symptoms, neurological and physical examinations, and response to certain medications. Bowman and his team will develop statistical algorithms that will filter through millions of different possible brain measurements to detect changes that indicate neuro-degeneration related to Parkinson's. This will help accurately distinguish groups that are more likely to develop Parkinson's, thus changing what is known about the disease, enabling diagnosis before the classic motor symptoms occur and potentially altering treatments.

The research project has two aims:

1. Imaging-based Biomarkers: Using imaging technology, the team will capture changes in brain activity, structure and pathology related to Parkinson's. A novel aspect of the research will be combining different types of imaging data as well as other biologic information to extract multidimensional Parkinson's disease biomarkers.

2. Utilization of Comprehensive Clinical Database Through a partnership with Kaiser Permanente of Georgia, the researchers will be able to access comprehensive, non-identifiable, patient medical records. They will compare and contrast medical histories, laboratory test results, medications and additional diagnoses to determine a risk-factor profile for Parkinson's.

All nine research groups funded by the NINDS will have access to each group's work through a web-based management system. The researchers will work together to apply their broad clinical and research expertise and samplings to their own research.

"The core of all of our research in the Parkinson's Disease Biomarker Program is to redefine Parkinson's," explains Bowman. "This program allows an avenue for researchers to unite, collaborate and ultimately expedite the advancement of understanding and treatment o
'/>"/>

Contact: Melva Robertson
melva.robertson@emory.edu
404-727-5692
Emory Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
2. NIH funds development of tissue chips to help predict drug safety
3. WaterSMART funds $1.7 million for science projects in desert and southern Rockies LCCs
4. EU FET program funds research on 3D neuronal structures mimicking human brain tissue
5. CIRM funds 6 UC San Diego stem cell researchers
6. NASA funds SAO instrument to track North American air pollution
7. Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries
8. Energy Deptartment funds UW project to turn wasted natural gas into diesel
9. NIH grant funds Boston College research into illnesses afflicting people living with HIV
10. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
11. Research reveals first evidence of hunting by prehistoric Ohioans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... 2008 Elsevier is pleased to announce that eight ... the annual BMA Medical Book Competition ceremony in London ... were highly commended and five received commendation. In total, ... 130 prizes awarded with 23 first prizes, 63 highly ...
... tie a mother to her newborn may be stronger in ... cesarean section, according to a study published by Yale School ... of Child Psychology and Psychiatry . The researchers, ... M.D., recruited two groups of parents from postpartum wards. One ...
... University of Cincinnati (UC) researchers have received a grant in ... of Aerospace Medicine to determine the ideal time to fly ... rush to move them from the battlefield into a safe ... getting these wounded soldiers to a cleaner, safer environment," explains ...
Cached Biology News:Elsevier congratulates its British Medical Association Award winning medical authors and editors 2Natural childbirth linked to stronger baby bonding than C-sections 2US Air Force grant targets medical evacuation procedures 2US Air Force grant targets medical evacuation procedures 3US Air Force grant targets medical evacuation procedures 4
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Recent action in Congress to reauthorize the U.S. ... address the social and ethical issues concerning the ... to address social and ethical issues now as ... nanotechnology and its possible significant contributions to our ...
... N.J., Jan. 27 Alfacell Corporation (OTC Bulletin Board: ... meeting with the U.S. Food and Drug Administration (FDA) ... components of the ONCONASE rolling New Drug Application (NDA) ... At the pre-NDA meeting, the FDA provided guidance ...
... Efficacy and Excellent TolerabilityCORONA, Calif., Jan. 27 Watson ... in generic and specialty branded pharmaceuticals, announced today that ... GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only ... with symptoms of urge urinary incontinence, urgency, and frequency. ...
Cached Biology Technology:Ethical evaluations of nanotechnology 2Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 4
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Ready-to-use solution....
ready-to-use solution...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: